AAAAAA
Results:
1-18
|
Results: 18
Authors:
Mansoor, A
Medeiros, LJ
Weber, DM
Alexanian, R
Hayes, K
Jones, D
Lai, R
Glassman, A
Bueso-Ramos, CE
Citation: A. Mansoor et al., Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia - Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course, AM J CLIN P, 116(4), 2001, pp. 543-549
Authors:
Shimoni, A
Smith, TL
Aleman, A
Weber, D
Dimopoulos, M
Anderlini, P
Andersson, B
Claxton, D
Ueno, NT
Khouri, I
Donato, M
Korbling, M
Alexanian, R
Champlin, R
Giralt, S
Citation: A. Shimoni et al., Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma, BONE MAR TR, 27(8), 2001, pp. 821-828
Authors:
Anagnostopoulos, A
Dimopoulos, MA
Aleman, A
Weber, D
Alexanian, R
Champlin, R
Giralt, S
Citation: A. Anagnostopoulos et al., High-dose chemotherapy - High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia, BONE MAR TR, 27(10), 2001, pp. 1027-1029
Authors:
Alexanian, R
Weber, D
Giralt, S
Dimopoulos, M
Delasalle, K
Smith, T
Champlin, R
Citation: R. Alexanian et al., Graft outcome - Impact of complete remission with intensive therapy in patients with responsive multiple myeloma, BONE MAR TR, 27(10), 2001, pp. 1037-1043
Authors:
Crowly, J
Jacobson, J
Alexanian, R
Citation: J. Crowly et al., Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience, SEM HEMATOL, 38(3), 2001, pp. 203-208
Authors:
Alexanian, R
Anderson, K
Barlogie, B
Berenson, J
Dalton, WS
Kyle, RA
Citation: R. Alexanian et al., Sydney E. Salmon, CLIN CANC R, 6(1), 2000, pp. 316-316
Authors:
Alexanian, R
Anderson, K
Barlogie, B
Berenson, J
Dalton, WS
Kyle, RA
Citation: R. Alexanian et al., Sydney E. Salmon, MD - In Memoriam, J CL ONCOL, 18(1), 2000, pp. 1-2
Authors:
Alexanian, R
Weber, D
Dimopoulos, M
Delasalle, K
Smith, TL
Citation: R. Alexanian et al., Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma, AM J HEMAT, 65(3), 2000, pp. 204-209
Authors:
Dimopoulos, MA
Moulopoulos, LA
Datseris, I
Weber, D
Delasalle, K
Gika, D
Alexanian, R
Citation: Ma. Dimopoulos et al., Imaging of myeloma bone disease - Implications for staging, prognosis and follow-up, ACTA ONCOL, 39(7), 2000, pp. 823-827
Authors:
Alexanian, R
Weber, D
Citation: R. Alexanian et D. Weber, Thalidomide for resistant and relapsing myeloma, SEM HEMATOL, 37(1), 2000, pp. 22-25
Authors:
Alexanian, R
Anderson, KC
Barlogie, B
Stirling, DI
Thomas, DA
Citation: R. Alexanian et al., Thalidomide in hematologic malignancies: Future directions, SEM HEMATOL, 37(1), 2000, pp. 35-39
Authors:
Dimopoulos, MA
Moulopoulos, LA
Maniatis, A
Alexanian, R
Citation: Ma. Dimopoulos et al., Solitary plasmacytoma of bone and asymptomatic multiple myeloma, BLOOD, 96(6), 2000, pp. 2037-2044
Authors:
Bergsagel, DE
Wong, O
Bergsagel, PL
Alexanian, R
Anderson, KC
Kyle, RA
Raabe, GK
Citation: De. Bergsagel et al., The causal relation between benzene exposure and multiple myeloma - Response: Benzene and multiple myeloma: scientific evidence, BLOOD, 95(4), 2000, pp. 1513-1514
Authors:
Liebross, RH
Ha, CS
Cox, JD
Weber, D
Delasalle, K
Alexanian, R
Citation: Rh. Liebross et al., Clinical course of solitary extramedullary plasmacytoma, RADIOTH ONC, 52(3), 1999, pp. 245-249
Authors:
Bergsagel, DE
Wong, O
Bergsagel, PL
Alexanian, R
Anderson, K
Kyle, RA
Raabe, GK
Citation: De. Bergsagel et al., Benzene and multiple myeloma: Appraisal of the scientific evidence, BLOOD, 94(4), 1999, pp. 1174-1182
Authors:
Keren, DF
Alexanian, R
Goeken, JA
Gorevic, PD
Kyle, RA
Tomar, RH
Citation: Df. Keren et al., Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies, ARCH PATH L, 123(2), 1999, pp. 106-107
Authors:
Alexanian, R
Weber, D
Liu, F
Citation: R. Alexanian et al., Differential diagnosis of monoclonal gammopathies, ARCH PATH L, 123(2), 1999, pp. 108-113
Authors:
Pasquali, S
Maqueo, JD
Vela, J
Kyle, RA
Leong, T
Fritz, E
Suciu, S
Palva, IP
Oivanen, T
Corrado, C
Lastiri, FJ
Peest, D
Kildahl-Andersen, O
Maniatis, A
Alison, R
Clarke, M
Evans, V
Gray, R
Greaves, E
Hall, E
Hicks, C
James, S
Peto, R
Richards, S
Sinclair, D
Tooth, A
Wheatley, K
Avvisati, G
Boccadoro, M
Bugliosi, R
Mandelli, F
Petrucci, MT
Pileri, A
Tribalto, M
Alexanian, R
Delasalle, KB
Child, J
Dunn, J
MacLennan, I
Milligan, D
Mellstedt, H
Osterborg, A
Hjorth, M
Holmberg, E
Rodjer, S
Westin, J
Kamiya, O
Shimizu, K
Bergsagel, DE
Shustik, C
Hippe, E
Kjaersgaard, E
Turesson, I
Westin, J
Riccardi, A
Ucci, G
Blade, J
Fontanillas, M
De Rosa, L
Montuoro, A
Bartolucci, AA
Omura, GA
Stagg, M
Salmon, S
Tangen, C
Jacobs, P
Wood, L
Levy, LM
Citation: S. Pasquali et al., Combination chemotherapy versus melphalan plus prednisone as treatment formultiple myeloma: An overview of 6,633 patients from 27 randomized trials, J CL ONCOL, 16(12), 1998, pp. 3832-3842
Risultati:
1-18
|